Key facts
- QurAlis’s last known valuation is $178.0M (Mar 2023).
- It has raised $158.4M across 4 recorded rounds; the latest was Early Stage VC ($20.0M) in Aug 2025.
- Notable investors include Alexandria Venture Investments, Johnson & Johnson Innovation - JLABS, Polaris Partners, Dolby Family Ventures, SV Health Investors — 21 tracked in total.
- QurAlis has filed 4 Form Ds with the SEC since 2020, most recently Sep 2025 ($20.0M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for QurAlis
Funding rounds
4 roundsAbout QurAlis
Developer of precision therapeutics and tools designed for amyotrophic lateral sclerosis and other neurodegenerative diseases with genetically validated targets. The company's proprietary platforms and biomarkers offer the design and development of drugs that act directly on disease-causing genetic alterations, advancing a robust precision medicine pipeline with therapeutic candidates that modify severe disease pathology in defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarker, enabling medical professionals to halt disease progression and significantly improve outcomes.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2016
- Employees
- 88
- Website
- quralis.com/
- Ownership
- Privately Held (backing)
QurAlis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in QurAlis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on QurAlis in its N-PORT filings yet. We sweep new filings monthly.